Delivering solutions to the next generation of cardiovascular medicines

JB Flinders, Senior Director, CVMER, Operational Strategy and Planning and Peter Alfinito, Executive Director, CVMER, Operational Strategy and Planning

Improving access to rare disease trials by incorporating DCT elements

Welcome to the February 2023 Labcorp Drug Development Decentralized Clinical Trial (DCT) blog. With Rare Disease Day coming soon on February 28, we are going to focus on how patients, sites and investigators can benefit by improving the design and execution of rare disease trials.

A conversation on PrEP and its impact on new HIV cases

Faster access to biopesticide alternatives to conventional pesticides under the U.S. BPPD regulatory framework

There is pressure worldwide for better, faster access to biological alternatives to conventional crop protection chemicals (CPCs). The U.S. Environmental Protection Agency (EPA) is ahead of regions such as the European Union (EU) in revising its regulatory approaches for biopesticides and in having a division dedicated to them, namely, the Biopesticides and Pollution Prevention Division (BPPD). Read on to discover how this can help you speed your biopesticide to market in the U.S. 

Innovative collaboration between Biomakers and Labcorp to provide greater access to oncology patients in Latin America

In December 2022, Labcorp and Biomakers signed an agreement that will positively impact thousands of cancer patients in Latin America through greater access to diagnostic molecular profiling and participation in clinical trials.

Labcorp Launches New Test for Risk Assessment and Prognosis of Severe Preeclampsia in Pregnant Women

B•R•A•H•M•S™ sFlt-1/PlGF KRYPTOR™ Test System is available through physicians and is the first FDA-cleared biomarker test to aid in the risk assessment of progression to preeclampsia with severe features, a leading cause of maternal and fetal mortality in the U.S. 1 BURLINGTON, N.C. , Jan.

A primary care approach to personalized asthma and allergy management

Enabling better access to kidney disease trials

March is National Kidney Month, and we at Labcorp are committed to improving the renal health of patients worldwide. The field of nephrology clinical research has been steadily adding new interventional trials over the last five years at an average pace of 176 trials per year. This activity reflects the continued interest in and importance of developing new drugs to treat renal disease. The recent approvals of Farxiga® (dapagliflozin) and Kerendia® (finerenone) have also moved the field forward with new treatments to delay kidney disease progression. However, the operational conduct of kidney disease studies—whether they be for chronic kidney disease or rare renal diseases such as IgA nephropathy or focal segmental glomerulosclerosis—remains challenging due to low recruitment rates, a widely competitive geographic spread and long development timelines. Within the Operational Strategy and Development Group at Labcorp, we are deploying various tactics to improve the efficiency of renal studies by focusing on the patient.

Program management services are now offered as part of Labcorp’s Preclinical Oncology Services

When it comes to discoveries in oncology, cancer patients can’t wait, which means neither can you. At Labcorp Preclinical Oncology, we understand there are many steps, phases and regulations to wade through to get to a lead drug candidate—all while time is of the utmost importance.

Alcohol-related liver disease: Inherent challenges and strategies for successful clinical trial conduct

The association between excessive alcohol consumption and liver disease is well documented. In fact, the effect on alcohol consumption levels during the COVID-19 pandemic has more recently been investigated. In a 2022 Hepatology article, researchers estimated that the one-year increase in alcohol consumption during the pandemic would result in an additional 8,000 deaths related to alcohol-associated liver disease (ALD) and 18,700 additional cases of decompensated cirrhosis in the United States alone. Similarly, in the United Kingdom, estimations show there was a 24% increase in the amount of alcohol supermarkets sold in the financial year 2020/2021 compared to the year before. Concurrently, alcohol-specific deaths increased by 20% in 2020, with ALD accounting for just over 80% of those deaths. With the only effective treatment for patients whose liver disease has become irreversible being transplantation, the impact of COVID-19 is significant: in 2021, the British Liver Trust estimated there was a 25% decrease in donors. It is therefore critically important that strategies to slow or halt the progression of this disease are implemented before the patient reaches end-stage liver disease.